CMTM8 (CKLF-like MARVEL transmembrane domain-containing protein 8) is a member of the chemokine-like factor (CKLF) superfamily, characterized by a conserved MARVEL domain involved in membrane apposition and vesicle trafficking. Located on human chromosome 3p22.3. CMTM8 is broadly expressed in tissues, including the prostate, liver, and immune cells. It functions as a tumor suppressor by regulating receptor tyrosine kinases (e.g., EGFR) and modulating signaling pathways like PI3K/AKT and MAPK/ERK. CMTM8 promotes receptor endocytosis and degradation, thereby inhibiting oncogenic signaling. It also interacts with immune checkpoints (e.g., PD-L1) and influences tumor microenvironment immunomodulation.
Antibodies targeting CMTM8 are essential tools for studying its expression, localization, and functional roles. They are used in techniques like Western blot, immunohistochemistry, and flow cytometry to investigate CMTM8's downregulation in cancers (e.g., prostate, lung, gastric, and liver cancers) and its correlation with poor prognosis. Research highlights its dual role in tumor suppression and immune regulation, suggesting therapeutic potential as a biomarker or target. CMTM8 antibodies thus support both basic research on cellular trafficking mechanisms and translational studies in oncology and immunology.